Therapeutic potential of fluoxetine in neurological disorders (Q34778793)

4 August 2017

1 reference

title

Therapeutic potential of fluoxetine in neurological disorders (English)

1 reference

4 August 2017

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

Jacques De Keyser

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

author name string

Jop P Mostert

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

Marco Heerings

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

Dorothea J Heersema

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

publication date

1 January 2008

1 reference

CNS Neuroscience & Therapeutics

4 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

page(s)

153-164

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

Mitochondria take center stage in aging and neurodegeneration

14 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Early-life fluoxetine exposure reduced functional deficits after hypoxic-ischemia brain injury in rat pups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Calcium: still center-stage in hypoxic-ischemic neuronal death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Cyclic AMP inhibition of tumor necrosis factor alpha production induced by amyloidogenic C-terminal peptide of Alzheimer's amyloid precursor protein in macrophages: involvement of multiple intracellular pathways and cyclic AMP response element bindi

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Short-term paroxetine treatment does not alter the motor response to levodopa in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

A controlled trial of fluoxetine in nondepressed patients with Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Antidepressants and seizures: clinical anecdotes overshadow neuroscience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine in the treatment of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Cognitive improvement with treatment of depression following mild traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Effects of antidepressant treatment with rTMS and fluoxetine on brain perfusion in PD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine's effects on cognitive performance in patients with traumatic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Molecular, pharmacological and functional diversity of 5-HT receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Human brain fluoxetine concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Norfluoxetine and fluoxetine have similar anticonvulsant and Ca2+ channel blocking potencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Up-regulation of 5-HT2B receptor density and receptor-mediated glycogenolysis in mouse astrocytes by long-term fluoxetine administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Function and regulation of CREB family transcription factors in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine increases the content of neurotrophic protein S100beta in the rat hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Apoptosis in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

MAP kinase activation by fluoxetine and its relation to gene expression in cultured rat astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Does fluoxetine have any effect on the cognition of patients with mild cognitive impairment? A double-blind, placebo-controlled, clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluvoxamine induced complex partial seizure in the treatment of bulimia nervosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Protection of ischemic rat spinal cord white matter: Dual action of KB-R7943 on Na+/Ca2+ exchange and L-type Ca2+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Anticonvulsant effects of acute and repeated fluoxetine treatment in unstressed and stressed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Seizure prophylaxis in an animal model of epilepsy by dietary fluoxetine supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

S100B in brain damage and neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Response of emotional unawareness after stroke to antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Citalopram as treatment of depression in patients with epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Increase of Parkinson disability after fluoxetine medication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

General mechanisms of axonal damage and its prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Transfer of glycogen-derived lactate from astrocytes to axons via specific monocarboxylate transporters supports mouse optic nerve activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Selective phosphorylation of nuclear CREB by fluoxetine is linked to activation of CaM kinase IV and MAP kinase cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-induced seizures in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Targeting energy metabolism in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

S100B protein is released by in vitro trauma and reduces delayed neuronal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Effects of fluoxetine on the 5-HT1A receptor and recovery of cognitive function after traumatic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine and recovery of motor function after focal ischemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Fluoxetine reduces L-DOPA-derived extracellular DA in the 6-OHDA-lesioned rat striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Behavioral and histological effects of chronic antipsychotic and antidepressant drug treatment in aged rats with focal ischemic brain injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

The effect of fluoxetine in a model of chemically induced seizures--behavioral and immunocytochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1527-3458.2008.00040.X

Evidence for neuroprotective effects of endogenous brain-derived neurotrophic factor after global forebrain ischemia in rats

21 January 2018

1 reference

12 December 2020

Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study

1 reference

12 December 2020

Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells

1 reference

12 December 2020

cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment.

1 reference

12 December 2020

Fluoxetine in early poststroke depression: a double-blind placebo-controlled study

1 reference

12 December 2020

Seizure possibly associated with fluvoxamine

1 reference

12 December 2020

A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease.

1 reference

12 December 2020

BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?

1 reference

12 December 2020

Glycogen regulation and functional role in mouse white matter

1 reference

12 December 2020

cAMP response element binding protein family transcription factors: the Holy Grail of neurological therapeutics?

1 reference

12 December 2020

Case history: the discovery of fluoxetine hydrochloride (Prozac)

1 reference

12 December 2020

Ions, energy and axonal injury: towards a molecular neurology of multiple sclerosis

1 reference

12 December 2020

Effect of fluoxetine on patients with multiple sclerosis

1 reference

12 December 2020

Fluvoxamine: an antidepressant with low (or no) epileptogenic effect

1 reference

12 December 2020

Exacerbation of symptoms of multiple sclerosis in a patient taking fluoxetine

1 reference

12 December 2020

Clinical pharmacology and pharmacokinetics of fluoxetine: a review.

1 reference

12 December 2020

Anticonvulsant effect of fluoxetine in humans

1 reference

12 December 2020

Further evidence that fluoxetine interacts with a 5-HT2C receptor in glial cells

1 reference

12 December 2020

Prolonged but not acute fluoxetine administration produces its inhibitory effect on hippocampal seizures in rats

1 reference

12 December 2020

Does fluoxetine aggravate Parkinson's disease? A pilot prospective study

1 reference

12 December 2020

Stimulation of glycogenolysis in astrocytes by fluoxetine, an antidepressant acting like 5-HT.

1 reference

12 December 2020

Hippocampal serotonin levels influence the expression of S100 beta detected by immunocytochemistry

1 reference

12 December 2020

Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus.

1 reference

12 December 2020

Fluoxetine in Parkinson's disease

1 reference

12 December 2020

Inhibition of neuronal Na+ channels by antidepressant drugs

1 reference

12 December 2020

Pilot study of haloperidol, fluoxetine, and placebo for agitation in Alzheimer's disease

1 reference

12 December 2020

10.1111/J.1527-3458.2008.00040.X

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nozhjdorbrae3a77rhrkekl7zq

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_nozhjdorbrae3a77rhrkekl7zq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nozhjdorbrae3a77rhrkekl7zq

30 July 2022

mapped directly with Wikidata item

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6494017&resulttype=core&format=json

14 May 2020

1 reference

https://api.fatcat.wiki/v0/release/nozhjdorbrae3a77rhrkekl7zq

30 July 2022